ycliper

Популярное

Музыка Кино и Анимация Автомобили Животные Спорт Путешествия Игры Юмор

Интересные видео

2025 Сериалы Трейлеры Новости Как сделать Видеоуроки Diy своими руками

Топ запросов

смотреть а4 schoolboy runaway турецкий сериал смотреть мультфильмы эдисон
Скачать

You need a

Автор: CURE SYNGAP1, 501(c)(3) fka SynGAP Research Fund

Загружено: 2025-09-26

Просмотров: 107

Описание: Friday, September 26, 2025. Week 39.

In #S10e182 I told you about CAMP4, don’t miss that, watch here:    • CURE SYNGAP1 joins biotech investors in CA...   Sharing research comments from William Blair & Wedbush

William Blair Initiation of Coverage: “Among several quality investors, the private placement included the Syngap Research Fund, which is active in the Syngap1 patient community and will be an important resource in aiding patient identification and enrollment in the Phase 1/2 trial in our view.”

Wedbush
Ph1/2 Will Likely Begin From Ex-U.S., Aiming for Early Intervention. Citing precedents of other intrathecally delivered antisense oligonucleotide programs for CNS indications, where the FDA oftentimes required sponsors to begin at a dose level well below the efficacious dose, CAMP plans to begin patient dosing outside the U.S. for the potential to go directly to doses that are expected to show efficacy. The selection of patient age range will depend on regulatory discussions, and management highlighted the impact of the disease on neurodevelopment, so early intervention could allow patients to have a better opportunity to achieve as normal as possible development.
CAMP Will Have Access to Natural History Data being Collected by SRF and CHOP. According to management, a natural history study is being conducted by SynGAP Research Fund (SRF), which also participated in the private placement, in collaboration with Children's Hospital of Philadelphia (CHOP), and CAMP will have access to data as well as patients for future clinical study enrollment.

Donate now: https://curesyngap1.org/donate/
Beacon of Hope was a great success, raised over $100k. We need to do this every year. Thanks to Navarros for getting this launched, also to Suzanne Jones, Emily Barnes, Peter Halliburton, & Kathryn Helde who helped make this event incredible.

Emmy’s video (top of) https://curesyngap1.org/resources/mov...
Blog: https://cureSYNGAP1.org/Beacon25 (will be live Friday night 9/26)
Pairs well with Gala Blog: https://curesyngap1.org/Gala25

Research is non-stop:
CRID, get one. https://curesyngap1.org/blog/every-sy...
ProMMiS, incredible coordination meeting today. Sign up. https://curesyngap1.org/resources/stu...
Sign up for Citizen Health too! AI Advocate is live for us an awesome. https://www.citizen.health/partners/srf

Episode 183 of #Syngap10 #CureSYNGAP1
#Advocate #PatientAdvocacy #UnmetNeed #SYNGAP1 #SynGAP #SynGAProMMiS

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...
You need a

Поделиться в:

Доступные форматы для скачивания:

Скачать видео

  • Информация по загрузке:

Скачать аудио

Похожие видео

DSC - RDCRN - NCATS - NIH Press!  #AAV in #Cell. SRF at CB. Scramble for SYNGAP1 next week! #S10e184

DSC - RDCRN - NCATS - NIH Press! #AAV in #Cell. SRF at CB. Scramble for SYNGAP1 next week! #S10e184

Clinical Research, AI Dx, #NL47, Survey, #Autism Press, 6 Days to Register for #SYNGAP1conf #S10e187

Clinical Research, AI Dx, #NL47, Survey, #Autism Press, 6 Days to Register for #SYNGAP1conf #S10e187

CURE SYNGAP1 Conference 2025: Science Day Session 4: ASO Therapy to Upregulate SYNGAP1 in SRD

CURE SYNGAP1 Conference 2025: Science Day Session 4: ASO Therapy to Upregulate SYNGAP1 in SRD

AES ‘25 was incredible, Fundraising, PRV, Behaviors, Posters/Pubmed & Thank you. #S10e192

AES ‘25 was incredible, Fundraising, PRV, Behaviors, Posters/Pubmed & Thank you. #S10e192

Sting - Shape of My Heart || Sylwester z Dwójką 2025

Sting - Shape of My Heart || Sylwester z Dwójką 2025

5 Hot Stocks to Buy Now: January's Top Picks With Upside Ahead

5 Hot Stocks to Buy Now: January's Top Picks With Upside Ahead

Good earnings and strong margins will continue this year, says Hightower's Stephanie Link

Good earnings and strong margins will continue this year, says Hightower's Stephanie Link

AAV.  Resources on cureSYNGAP1.org.  Congrats to Ultragenyx & Novartis. Conf is in 5 days! #S10e190

AAV. Resources on cureSYNGAP1.org. Congrats to Ultragenyx & Novartis. Conf is in 5 days! #S10e190

Top 7 Stocks to BUY NOW for 2026 (High Growth Stocks)

Top 7 Stocks to BUY NOW for 2026 (High Growth Stocks)

CURE SYNGAP1 Conference 2025: Science Day Session 6: Fireside Chat

CURE SYNGAP1 Conference 2025: Science Day Session 6: Fireside Chat

Informacje Telewizja Republika 02.01.2026 godzina 12:30

Informacje Telewizja Republika 02.01.2026 godzina 12:30

New book by #SYNGAP1 mom for and about #GlassChild (Sibling of Special Needs) #S10e191

New book by #SYNGAP1 mom for and about #GlassChild (Sibling of Special Needs) #S10e191

Pożar w Szwajcarii. Zakazany pokaz zakończony katastrofą

Pożar w Szwajcarii. Zakazany pokaz zakończony katastrofą

CURE SYNGAP1 | Missense Webinar SMART Program

CURE SYNGAP1 | Missense Webinar SMART Program

SYNGAP10 - Ep 1 - 12 March 2021 - Mike Graglia updates Syngap Families on the work of SRF

SYNGAP10 - Ep 1 - 12 March 2021 - Mike Graglia updates Syngap Families on the work of SRF

Mróz do -20°C w prognozach do 15 stycznia. Później wypchnięcie arktycznego powietrza. Omówienie

Mróz do -20°C w prognozach do 15 stycznia. Później wypchnięcie arktycznego powietrza. Omówienie

#SyngapCenus 1,675 Teacher Handout CC/VNS Citizen Paper $CAMP starts GLP Tox CIRM funds S1 #S10e186

#SyngapCenus 1,675 Teacher Handout CC/VNS Citizen Paper $CAMP starts GLP Tox CIRM funds S1 #S10e186

If You're Over 65: Stanley Druckenmiller's Simple Portfolio That Never Fails

If You're Over 65: Stanley Druckenmiller's Simple Portfolio That Never Fails

Luksusowe dziewczyny to była pseudoafera?

Luksusowe dziewczyny to była pseudoafera?

© 2025 ycliper. Все права защищены.



  • Контакты
  • О нас
  • Политика конфиденциальности



Контакты для правообладателей: [email protected]